
    
      Women invited to participate in this study must be post-menopausal and be 18 years of age or
      older. The study is being performed on a total of 100 individuals. Of this group, 75 will be
      in the Treatment Groups using Fulvestrant/Anastrozole with our without bevacizumab and 25
      will be in the "Best Supportive Care" groups receiving no treatment or just bevacizumab at
      the University of Pittsburgh Medical Center.
    
  